文献速递肿瘤 PET/CT

基于关联证据方法评估18F-FDG PET/CT对非首选手术的晚期黑色素瘤患者临床管理与结局的影响

Influence of 18F-FDG PET/CT on clinical management and outcome in patients with advanced melanoma not primarily selected for surgery based on a linked evidence approach.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-03-02

该研究基于前瞻性肿瘤PET/CT登记数据,分析119例晚期黑色素瘤患者(非首选手术)共201次18F-FDG PET/CT检查对临床管理的影响,并采用关联证据方法结合生存数据与文献诊断准确性评估预期获益。结果显示48%的检查后发生管理改变(38%重大改变,10%次要改变),PET/CT判断为无肿瘤或适合根治性手术的患者5年生存率较接受系统治疗者 approximately 翻倍。

要点

  • 非首选手术的晚期黑色素瘤患者中,48%的PET/CT检查后发生管理改变,其中38%为重大改变。
  • PET/CT判断为无肿瘤或适合根治性手术的患者,5年生存率较系统治疗者 approximately 翻倍。
  • 基于文献诊断准确性与治疗效应,PET/CT引导的管理改变与相关预期临床获益有关。

核心结论

  • 在非首选手术的晚期黑色素瘤患者中,PET/CT使用导致频繁的管理改变,并与相关预期临床获益有关,尤其在PET/CT分类为无肿瘤或适合根治性手术的患者中。

研究设计与样本

  • 研究分析了119例晚期黑色素瘤患者的201次18F-FDG PET/CT检查(III期33次,IV期168次),患者来自前瞻性肿瘤PET/CT登记,非首选手术。
  • PET/CT指征分为常规影像病灶不明确(n=8)、多次手术后常规随访(n=115)和系统治疗疗效评估(n=78)。
  • 管理改变分为重大改变(随访转为手术或系统治疗或反之、手术转为系统治疗或反之)和次要改变(系统治疗调整)。
  • 采用关联证据方法连接登记数据、总生存结局数据及基于现有文献的PET/CT诊断准确性证据,确定改变的预期获益。

主要发现

  • 全部201次检查中,48%出现管理改变,包括10%次要改变和38%重大改变。
  • 重大改变包括从随访(33/201)或治疗暂停(7/201)转为系统治疗、转为手术或其他局部治疗(26/201)以及最佳支持治疗(2/201)。
  • 201次检查中有9例导致系统治疗暂停。
  • 与接受系统治疗的患者相比,肿瘤排除后随访或接受局部治疗的患者5年生存率 approximately 翻倍。

临床怎么用

  • 作者认为,基于文献的准确性与治疗效应结果,PET/CT引导的管理改变与患者获益有关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the clinical benefit of positron emission tomography (PET)/computed tomography (CT) in patients with advanced melanoma, primarily not selected for surgery based on management changes and survival data using the linked evidence approach (LEA). METHODS: A total of 201 18F-FDG PET/CT examinations (n = 33, stage III and n = 168, stage IV) in 119 melanoma patients, primarily not scheduled for surgery, were analysed regarding their impact on clinical management. Patients were selected from a prospective oncological PET/CT registry. The three PET/CT indication groups included unclear lesions in conventional imaging (n = 8), routine follow-up after multiple surgeries (n = 115) and therapy response evaluation of systemic therapy (n = 78). PET/CT-induced management changes were categorized either as major (change from follow-up to surgical or systemic treatment or vice versa, change from surgery to systemic therapy or vice versa) or minor (modifications in systemic therapy). The expected benefit of changes was determined via the linked evidence approach (LEA) connecting registry data, outcome data including overall survival and evidence of diagnostic accuracy of PET/CT based on existing literature. RESULTS: Related to the total study cohort, a change of management after PET/CT was observed in 48% of scans, including 10% minor and 38% major changes. Major changes involved a shift either from follow-up (33/201) or therapy pause (7/201) to systemic therapy, to surgical or other local therapy (26/201) and BSC (2/201). Nine out of 201 cases resulted in treatment pause of systemic therapy. We could confirm the prognostic value of PET/CT-based management by observing a 5-year survival rate more than roughly doubled in patients followed up after tumour exclusion or under local therapy compared with patients under systemic therapy. We could argue for a patient benefit from PET/CT-based management changes using results on accuracy and therapeutic effects from the literature. CONCLUSION: The use of PET/CT in advanced melanoma patients, primarily not considered for surgery, resulted in frequent changes of management associated with a relevant expected clinical benefit especially in patients classified by PET/CT as tumour-free or eligible for radical surgery.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Olthof SC, Forschner A, Martus P, et al. Influence of 18F-FDG PET/CT on clinical management and outcome in patients with advanced melanoma not primarily selected for surgery based on a linked evidence approach. Eur J Nucl Med Mol Imaging. 2020. PMID: 32123968. doi:10.1007/s00259-020-04733-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。